Equities research analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to post sales of $86.09 million for the current quarter, Zacks reports. Six analysts have made estimates for Genomic Health’s earnings, with the highest sales estimate coming in at $86.44 million and the lowest estimate coming in at $86.00 million. Genomic Health posted sales of $81.97 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 5%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 1st.

On average, analysts expect that Genomic Health will report full-year sales of $86.09 million for the current year, with estimates ranging from $352.49 million to $358.37 million. For the next financial year, analysts expect that the company will post sales of $393.45 million per share, with estimates ranging from $389.71 million to $400.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Genomic Health.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, May 9th. The medical research company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.01. Genomic Health had a negative return on equity of 6.80% and a negative net margin of 2.53%. The company had revenue of $84 million during the quarter, compared to the consensus estimate of $86.21 million. During the same period in the prior year, the firm posted ($0.19) earnings per share. The company’s revenue was up 3.8% on a year-over-year basis.

Several research firms recently issued reports on GHDX. TheStreet raised shares of Genomic Health from a “d+” rating to a “c-” rating in a research report on Monday, February 27th. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price target on shares of Genomic Health in a research report on Monday, June 12th. Raymond James Financial, Inc. reissued a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 18th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $32.00.

Genomic Health (NASDAQ GHDX) traded up 0.30% during midday trading on Thursday, hitting $33.57. 20,487 shares of the company were exchanged. The firm’s 50-day moving average price is $31.42 and its 200-day moving average price is $30.49. The stock’s market capitalization is $1.15 billion. Genomic Health has a one year low of $24.81 and a one year high of $33.97.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect Genomic Health, Inc. (GHDX) Will Announce Quarterly Sales of $86.09 Million” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/22/zacks-brokerages-expect-genomic-health-inc-ghdx-will-announce-quarterly-sales-of-86-09-million.html.

In other news, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction on Monday, June 5th. The stock was sold at an average price of $32.32, for a total transaction of $161,600.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Fred E. Cohen sold 8,250 shares of Genomic Health stock in a transaction on Friday, May 19th. The stock was sold at an average price of $29.54, for a total value of $243,705.00. Following the sale, the director now owns 74,145 shares in the company, valued at $2,190,243.30. The disclosure for this sale can be found here. Insiders have sold a total of 58,000 shares of company stock worth $1,771,085 over the last quarter. Company insiders own 47.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Pacad Investment Ltd. acquired a new stake in Genomic Health during the fourth quarter worth approximately $118,000. Dubuque Bank & Trust Co. purchased a new stake in shares of Genomic Health during the first quarter worth about $142,000. Legal & General Group Plc boosted its stake in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after buying an additional 2,038 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Genomic Health during the first quarter worth about $218,000. Finally, Stonebridge Capital Management Inc. purchased a new stake in shares of Genomic Health during the first quarter worth about $259,000. Institutional investors own 89.49% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.